tbuckley/cabot-search huggingface dataset:
Procollagen‐3 <i>N</i> ‐terminal peptide measurements for the detection of liver fibrosis in methotrexate‐treated patients with psoriasis: daily practice use and clinical implications
Authors: J.M.P.A. Reek, S.P. Menting, W.W.L. Janssen, R. Dhaliwal, A.C. Heijboer, A.E. Herwaarden, F.C.G.J. Sweep, L.M. Jong, E.T. Tjwa, M.E. Otero, P.I. Spuls, E.M.G.J. Jong
Journal: British Journal of Dermatology (2017)

In the past, a varying incidence of liver fibrosis, which was attributed to methotrexate (MTX) treatment for psoriasis, has been reported.(1-5) However, recent reports show lower incidences of liver fibrosis in this group, and a low or absent risk attributable to MTX.(6,7) Dawwas et al. found that end-stage liver disease related to MTX was very uncommon (0.07% of 158 904 liver transplant patients), and that features of the metabolic syndrome were prevalent in those affected.(6) This article is protected by copyright. All rights reserved
Anti-HPA-9bw (Maxa+) Feto-Maternal Alloimmunization and Clinically Severe Neonatal Thrombocytopenia: Difficulties in Diagnosis and Therapy, Report on 12 Cases.
Authors: Cecile Kaplan-Gouet, Leendert Porcelijn, Philippe Vanlieferinghen, Eric Julien, Frederic Bianchi, Corinne Martageix, Vincent Jallu
Journal: Blood (2004)
Genetic Variability of the CLEC4M Endothelial Lectin Receptor Modulates Binding and Internalization of Von Willebrand Factor and Contributes to Variance in Plasma VWF Levels
Authors: Laura L. Swystun, Natalia Rydz, Colleen Notley, Jonathan J. Riches, Andrew D Paterson, Robert R. Montgomery, Paula D. James, David Lillicrap
Journal: Blood (2012)
The Influence of PET/Gallium (PET/Gal) Status and High-Dose Rituximab (HDR) in Patients with Aggressive, Large, B-Cell Lymphoma (LBCL) Receiving Autologous Stem Cell Transplants (ASCT).
Authors: Amin M. Alousi, Rima M. Saliba, Grace-Julia Okoroji, Chitra Hosing, Barry I. Samuels, Richard E. Champlin, Issa F. Khouri
Journal: Blood (2006)
Primary Bone Marrow-Derived MSC Subsets Have Distinct Wnt-Signatures Compared to Conventionally Cultured MSC and Differ in Their Capacity to Support Hematopoiesis in Vitro,
Authors: Marijke W Maijenburg, Marion Kleijer, Kim Vermeul, Erik P.J. Mul, Floris P.J. van Alphen, C. Ellen van der Schoot, Carlijn Voermans
Journal: Blood (2011)
Early Absolute Lymphocyte Count Recovery after Autologous Peripheral Hematopoietic Stem Cell Transplantation Depends on the Pre-Mobilization Absolute Lymphocyte Count and the Lymphocyte Dose in the Autograft.
Authors: Elias H. Atta, Cláudia J.P.B. Coelho, Silvia M.P. Sarcinelli, Cláudia A. Máximo, Alexandre M. Azevedo, Vera L.N. Marra, Clarisse Lobo
Journal: Blood (2007)
Multimodality detection of multicentric breast cancer
Authors: M. Chaudhry, M. Schnall, A. Alavi, M. Putt
Journal: Journal of Clinical Oncology (2005)

624 Background: It is important to establish the local extent of breast cancer in order to make an informed decision with regard to therapeutic approach. The relative performance of the available breast imaging modalities with respect to the detection of multicentric cancer has not been established. This study is aimed at comparing MRI, Sonography, FSM, DM and FDG-PET in the detection of multicentric disease in a patient with known breast cancer. Methods: Women with a positive biopsy for breast cancer or Birads category5 mammogram were eligible. Imaging included MRI, Ultrasound, Digital mammography and PET. All examinations were interpreted with knowledge of initial Film screen findings, clinical exam findings and any relevant history. Modalities were interpreted by different radiologists initially blinded to other modalities and then a consensus was developed. Birads assessment was assigned to each finding. Results: A total of 86 patients with 87 incidental lesions in the ipsilateral breast were analyzed. 43 incidental lesions (separate from the index cancer) in 35 patients were felt to be suspicious for multicentric cancers on consensus. To date, 26 women underwent biopsy of their incidental lesions which yielded 23 cases of multicentric cancer. Of these 23 cases of multicentric cancer, 14 were identified on MRI, 11 on sonography, 7 on digital mammography and 5 on film screen mammography and 1 on PET. Conclusions: MRI had the highest yield for multicentric cancer followed by Sonography and X-ray mammography. PET has the lowest yield. No significant financial relationships to disclose.
Margaret McCartney: The NHS needs a new era of political leadership
Authors: Margaret McCartney
Journal: BMJ (2017)

The chairs of the Health Committee, Public Accounts Committee, and Communities and Local Government Committee have written to the government calling for a “new political consensus” on UK health and social care. They note the “immense challenge” of ensuring adequate social care in the coming decades and think that this “can best be achieved if there is cross party consensus.”

For a long time the prevailing political narrative has been that the holy grails of individual leadership, technology, and innovation will “save the NHS.” In practice, this has led to …
ARRY-429520, a Novel KSP Inhibitor with Potent Anti-Proliferative Activity in Leukemic Cell Lines.
Authors: Christine Lemieux, Walt DeWolf, Walt Voegtli, Eli Wallace, Rich Woessner, Chris Corrette, Shelley Allen, Jeremy Hans, Qian Zhao, Tom Aicher, Joe Lyssikatos, John Robinson, Kevin Koch, James Winkler, Stefan Gross
Journal: Blood (2006)
Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma
Authors: Peter Martin, Zhengming Chen, Bruce D. Cheson, Tricia Ellis, Katherine Sue Robinson, Michael E. Williams, Saurabh A. Rajguru, Jonathan W. Friedberg, Richard H. van der Jagt, Ann S. LaCasce, Robin Joyce, Kristen N. Ganjoo, Nancy L Bartlett, Bernard Lemieux, Ari M. Vander Walde, Jordan A. Herst, Jeffrey Szer, Michael H. Bar, Fernando Cabanillas, Anthony J. Dodds, Paul G. Montgomery, Bryn Pressnail, Mitchell R. Smith, John P. Leonard
Journal: Blood (2015)
Interdisciplinary Evidence-Based Guideline for Diagnosis, Therapy and Follow-up of Adult Hodgkin Lymphoma Patients
Authors: Michaela Rancea, Andreas Engert, Peter Borchmann, Bastian von Tresckow, Teresa Halbsguth, Karolin Behringer, Diana Wongso, Boris Böll, Beate Klimm, Indra Thielen, Dennis A. Eichenauer, Nicole Skoetz
Journal: Blood (2012)
Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors
Authors: Kathy L McGraw, Ashley A Basiorka, Joseph Johnson, Justine Clark, Gisela Caceres, Eric Padron, Ruth Heaton, Yukiyasu Ozawa, Sheng Wei, Lubomir Sokol, Alan F List
Journal: Blood (2014)
Autologous Stem Cell Transplantation with Benda-Eam (Bendamustine, Etoposide, Cytarabine, Melphalan) in Aggressive Non Hodgkin and Hodgkin´s Lymphoma
Authors: Thomas Noesslinger, Michael Panny, Michaela Moestl, Elisabeth Koller, Felix Keil
Journal: Blood (2016)
Rituximab Maintenance Therapy in Diffuse Large B-Cell Lymphoma in a Multicenter Prospective Randomised Phase II Study,
Authors: Mathias Witzens-Harig, Axel Benner, Michael Rieger, Fabienne McClanahan, Manfred Hensel, Kai Neben, Peter Dreger, Eva Lengfelder, Ingo Schmidt-Wolf, Alwin Krämer, Anthony D. Ho
Journal: Blood (2011)
Dual HDAC and PI3K Inhibitor, CUDC-907 Alone or in Combination with ABL Tyrosine Kinase Inhibitor Against ABL Tyrosine Kinase Inhibitor Resistant Leukemia Cells
Authors: Seiichi Okabe, Tetsuzo Tauchi, Yuko Tanaka, Juri Sakuta, Kazuma Ohyashiki
Journal: Blood (2015)
Reply to the Letter to the editor ‘Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial’ by Fornaro et al.
Authors: M. Ikeda, S. Shimizu, T. Sato, M. Morimoto, Y. Kojima, Y. Inaba, A. Hagihara, M. Kudo, S. Nakamori, S. Kaneko, R. Sugimoto, T. Tahara, T. Ohmura, K. Yasui, K. Sato, H. Ishii, J. Furuse, T. Okusaka
Journal: Annals of Oncology (2017)
A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma.
Authors: James Berenson, Jeff Matous, Delina Ferretti, Regina Swift, Russell Mapes, Blake Morrison, Howard Yeh, Sal Bevivino
Journal: Blood (2005)
Expression of Cancer-Testis Antigens MAGE-C1/CT7 and MAGE-A3 Is Central to the Survival of Myeloma Cells and Their Resistance to Chemotherapy
Authors: Djordje Atanackovic, York Hildebrandt, Adam Jadczak, Tim Luetkens, Sabrina Meyer, Katrin Bartels, Yanran Cao, Axel R. Zander, Carsten Bokemeyer, Nicolaus Kroeger
Journal: Blood (2008)
Mutational Analysis of Chronic Phase Chronic Myeloid Leukemia (CMLCP) Clones Reveals Heightened BCR-ABL1 Genetic Instability in Patients Failing Sequential Imatinib and Dasatinib Therapy.
Authors: Alfonso QuintasCardama, Don L. Gibbons, Hagop M. Kantarjian, Moshe Talpaz, Nicholas Donato, Jorge Cortes
Journal: Blood (2008)
PS1145, a novel nuclear factor-kappa B inhibitor, downregulates the proangiogenic factor Interleukin-8 in human bladder cancer cells
Authors: Ralph A. Highshaw, Colin P. Dinney, David J. McConkey
Journal: Cancer Research (2005)

3028   Introduction and Objective: Interleukin (IL)-8 is an important mediator of angiogenesis in transitional cell carcinoma (TCC) of the bladder. IL-8 transcription is controlled by nuclear factor kappa B (NF-κB). PS-1145 is a novel inhibitor of I-kappa B kinase (IKK) which is the upstream activator of NF-kB. The purpose of this study was to investigate the effects of PS-1145 on IL-8 expression and cell death in the RT4 (TCC) cell line. Methods: NF-κB activity was measured by electromobility gel shift assays (EMSA). Protein and mRNA levels of IL-8 and vascular endothelial growth factor (VEGF) were determined by enzyme-linked immunosorbent assay (ELISA) and RNase protection assays (RPA) respectively. Apoptosis was measured by propidium iodide (PI) staining followed by FACS analysis. Results: Preliminary experiments demonstrated that NF-κB was constitutively active in RT4 bladder cancer cells and PS-1145 inhibited both basal and tumor necrosis factor- inducible NF-κB activity in a concentration-dependent fashion. ELISA analyses demonstrated that PS-1145 also significantly reduced IL-8, but not VEGF protein production. PS-1145 RPA analyses confirmed that decreased IL-8 mRNA levels by 24 hours in a concentration- dependent fashion (50% inhibition at 10 micromoles and 90% at 50 micromoles). Interestingly, PS-1145, also partially decreased VEGF mRNA levels (isoforms 165 and 189). However, these effects did not translate into decreases in VEGF protein expression. PS-1145 did not induce significant levels of apoptosis as measured by PI staining and FACS analyses, even at 50 micromolar concentrations, indicating that the effects on IL-8 expression were not caused by cell death. Conclusions: These results demonstrate that PS1145 is a potent inhibitor of NF-κB and IL-8 expression. Since NF-κB activity has been implicated in chemoresistance, PS-1145 should be evaluated in combination with conventional chemotherapy. Future studies will also investigate the efficacy of PS-1145 in combination with chemotherapeutic agents in both  in vitro  and  in vivo  orthotopic bladder cancer models.
Wearable Technology and Long-term Weight Loss—Reply
Authors: John M. Jakicic, Steven H. Belle
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The TWENTE Trial in Perspective
Authors: Dean J. Kereiakes
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Ikaros Is a Frequently Affected Hematopoietic Differentiation Factor in Pediatric Relapse-Prone Precursor B-Cell Acute Lymphoblastic Leukemia
Authors: Roland P. Kuiper, Frank N. van Leeuwen, Vincent van der Velden, Simon V. van Reijmersdal, Jeltje de Vries, Suzanne T.M. Keijzers-Vloet, Jayne Hehir-Kwa, E. van Wering, Jacques JM van Dongen, Peter M. Hoogerbrugge, Ad Geurts van Kessel
Journal: Blood (2008)
Association of Cth Genetic Variant with Veno-Occlusive Disease in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell Transplantation.
Authors: Patricia Huezo-Diaz, Chakradhara Rao Uppungunduri, Anuj Kumar Tyagi, Mohamed Aziz Rezgui, Fabienne Gumy-Pause, Michel Duval, Henrique Bittencourt, Maja Krajinovic, Marc Ansari
Journal: Blood (2012)
Age and Response after Autologous Stem Cell Transplantation (ASCT) Define a Group of Long-Term Event-Free Survivors among Patients (Pts) with Low-Grade Follicular Lymphoma (FL): A Single Institution Experience.
Authors: Charalambos Andreadis, Elise A. Chong, Edward A. Stadtmauer, Selina M. Luger, David L. Porter, Donald Tsai, Sunita Nasta, Rebecca Elstrom, Steven Goldstein, Lisa Downs, Kathleen Cunningham, Kimberly Hummel, Stephen J. Schuster
Journal: Blood (2004)
Focal Cortical Dysplasia: Gene Mutations, Cell Signaling, and Therapeutic Implications
Authors: Philip H. Iffland, Peter B. Crino
Journal: Annual Review of Pathology Mechanisms of Disease (2017)

Focal cortical dysplasias (FCDs) are malformations of cortical development (MCDs) that are highly associated with medication-resistant epilepsy and are the most common cause of neocortical epilepsy in children. FCDs are a heterogeneous group of developmental disorders caused by germline or somatic mutations that occur in genes regulating the PI3K/Akt/mTOR pathway—a key pathway in neuronal growth and migration. Accordingly, FCDs are characterized by abnormal cortical lamination, cell morphology (e.g., cytomegaly), and cellular polarity. In some FCD subtypes, balloon cells express proteins typically seen in neuroglial progenitor cells. Because recurrent intractable seizures are a common feature of FCDs, epileptogenic electrophysiological properties are also observed in addition to local inflammation. Here, we will summarize the current literature regarding FCDs, addressing the current classification system, histopathology, molecular genetics, electrophysiology, and transcriptome and cell signaling changes.
Accepting patients into emergency departments takes too long, says watchdog
Authors: Matthew Limb
Journal: BMJ (2017)

Half a million “ambulance hours” were lost in 2015-16 because of long transfers of care at hospital emergency departments, the National Audit Office (NAO) has found.1

The watchdog said that slow turnarounds at emergency departments, where staff are often too busy to receive patients, can pose safety risks and are symptomatic of wider NHS pressures. Ambulance services in England are struggling to cope with rising demand for urgent and emergency care amid staffing and funding constraints, and the system needs to work better as a whole, it added.

Amyas Morse, head of the NAO, said, “Until clinical commissioning groups see ambulance services as an integral part of that system …
胃切除後の空腸パウチ・ダブルトラクト法(JPD)再建の役割
Authors: Soeda J, Ogoshi K, Nakamura K, Nabeshima K, Okamoto Y, Morita M, Kondoh Y, Makuuti H, Nakui M, Kawasima T
Journal: Annals of Oncology (2007)
Venous thromboembolism in patients with renal cell carcinoma: Incidence, risk factors, and prognostic implication.
Authors: Ha-young Lee, Eunhee Park, Soohyeon Lee, Soojung Hong, Hyun Jung Park, Sang Joon Shin, Hyo Song Kim, Sun Young Rha
Journal: Journal of Clinical Oncology (2012)

446 Background: Renal cell ca (RCC) is one of solid tumor with relatively highest incidence of venous thromboembolism (VTE). But, there have been to no large-scale studies that focused on VTE in RCC. The aim of this study was to investigate the incidence, time course of VTE, risk factors, and prognosis associated with VTE in RCC patients in Korea. Methods: The medical records of RCC patients (n=1248) histologically diagnosed at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea from Jan 2005 to Mar 2011 were retrospectively reviewed. Results: Among 1248 RCC patients, 69.6% were men, median age was 56years (range: 4∼89), and stage distribution was stage I 65.1%, stage II 9.2%, stage III 10.4%, stage IV 12.5%. The 2-year cumulative incidences of tumor induced VTE (tVTE) was detected in 78 patients (6.3%), while 1-month, 6-months and 1-year cumulative incidence of tVTE were 5.3%, 5.7% and 6.0%, retrospectively. Two-year cumulative incidence of tVTE seemed to increase with stage (0.6%, 3.5%, 22.3% and 24.3% in stages I, II, III and IV, retrospectively). Almost tVTE events developed in the first few months after diagnosis. Stage and metastatic disease were independent risk factors for developing tVTE. In multivariate analysis, the development of tVTE was a significant predictor of survival (P=0.004) and stage, age, ECOG PS was also independent predictor of survival. Conclusions: This is the first study that specially focused on tVTE in RCC. The 2-year cumulative incidence of tVTE in Korean patients with RCC was 6.3%, which is similar to other ethnic group. As tVTE related to poorer survival, RCC patients with advanced stage and metastasis with higher risk of tVTE, close follow-up is recommended and proactive prophylaxis of VTE might be needed.
Congenital Heart Disease in Adults
Authors: Ariane J. Marelli
Journal: Circulation (1998)

“… it is the past that is in front of us; it is the future that lies behind us.” —James Downy



The diagnosis and treatment of congenital heart disease is one of the greatest medical success stories witnessed in the latter half of the 20th century. An estimated 32 000 infants with newly diagnosed congenital cardiovascular lesions are born in the United States each year. First-year mortality rates have dropped 50% since the l960s. Currently, ≈80% of first-year survivors live to reach adulthood. By the year 2000, the estimated prevalence of adults with congenital heart disease in the United States alone is expected to approach 1 million.1 

The result of converging advances in medicine, pediatrics, and cardiovascular surgery, this achievement highlights the impact of a well-crafted multidisciplinary collaborative effort. In that spirit, Perloff and Child have published …
An Anti-Apoptotic Molecule, Anamorsin, Is Upregulated in Anemia and Essential for Imperative Erytropoiesis
Authors: Akira Tanimura, Hirohiko Shibayama, Hamanaka Yuri, Natsuko Fujita, Nagate Yasuhiro, Tomohiko Ishibashi, Norimitsu Saitoh, Michiko Ichii, Takafumi Yokota, Sachiko Ezoe, Kenji Oritani, Yuzuru Kanakura
Journal: Blood (2014)
Constitutional Segmental Uniparental Disomy in a Twin Pair with t(12;21) Positive Acute Lymphoblastic Leukemia Characterized by the Same Prenatal Clone and Divergent Clonal Evolution.
Authors: Giovanni Cazzaniga, Julie Irving, Marco Citterio, Silvia Bungaro, Roxane Tussiwand, Rossella Mura, Andrew G. Hall, Andrea Biondi
Journal: Blood (2005)
Safety and Efficacy of a 12-week Maintenance Interval in Patients Treated with Imported Fire Ant Immunotherapy: An Interim Update
Authors: Rebecca Schapira, Kathryn P. Edwards, Derek M. Smith, Thad L. Ocampo, Shayne C. Stokes, Kevin Michael White, Kirk H. Waibel, Mike Tankersley, Karla E. Adams
Journal: Journal of Allergy and Clinical Immunology (2018)
Combined Effects of Pravastatin and Probucol on High-Density Lipoprotein Apolipoprotein A-I Kinetics in Cholesterol-fed Rabbits.
Authors: Keijiro Saku, Rui Liu, Shiro Jimi, Kunihiro Matsuo, Kyosuke Yamamoto, Teruyoshi Yanagita, Kikuo Arakawa
Journal: Circulation (1995)

The combined effects of pravastatin and probucol on high- density lipoprotein (HDL) apolipoprotein (apo) A-I kinetics in cholesterol (Ch)-fed rabbits were investigated. Japanese White rabbits were treated with 0.15% pravastatin and 0.5% Ch (group 1) or 0.15% pravastatin plus 1% probucol and 0.5% Ch (group 2) for 2 months. After treatment, the serum total cholesterol levels in groups 1 and 2 had significantly (p < 0.01) increased (37.4 +/- 6.7 mg/dl vs 117.1 +/- 46.4 mg/dl, and 31.4 +/- 4.9 mg/dl vs 143.0 +/- 84.5 mg /dl, respectively). The serum HDL-cholesterol levels in both groups decreased (18.2 +/- 2.8 mg/dl, vs 16.2 +/- 3.7 mg/dl p < 0.01 for group 1; 18.2 +/- 1.9 mg/dl vs 15.5 +/- 4.5 mg/dl, ns for group 2). Apo A-I kinetics were assessed by injecting (125)I-labeled HDL intravenously into both groups of rabbits, and taking blood samples periodically for 6 days. Kinetic parameters calculated from apo A-I specific radioactivity decay curves showed that the apo A-I fractional catabolic rates in rabbits fed pravastatin and Ch (group 1) were significantly less than those in rabbits fed pravastatin plus probucol and Ch (group 2) (0.546 +/- 0.017 /day vs 0.730 +/- 0.126 /day, p < 0.05), while the synthetic rate of apo A-I was lower in group 2 than in group 1 (14.76 +/- 1.71 mg/kg per day vs 11.21 +/- 2.38 mg/kg per day, respectively, p < 0.01). These data indicate that pravastatin and probucol have different effects on HDL-apo A-I kinetics in a diet which includes cholesterol.
Decitabine in Myelodysplastic Syndromes: Argentine Initial Multi-Institutional Clinical Experience
Authors: Marcelo Iastrebner, Virginia Prates, Jorge Arbelbide, Isolda Fernandez, Gabriela Flores, Gustavo Milone, Federico Sackmann, Silvia Saba, Sergio Orlando, Alfredo Basso, Astrid Pavlovsky, Gustavo Taborda, Jorge Korin, Julio Pose
Journal: Blood (2008)
NVP-BEZ235, A Dual Inhibitor of Phosphoinositol-3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), Is a Potent Inhibitor of Lymphoma Cell Growth and Survival
Authors: Daniela Buglio, Manuela Lemoine, Sattva S. Neelapu, Francisco Vega, Donald Berry, Anas Younes
Journal: Blood (2011)